Sphingolipidoses – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033
Sphingolipidoses are a group of inherited metabolic storage disorders characterized by the accumulation of glycosphingolipids and phosphosphingolipids, which share a hydrophobic ceramide component in their structure. Hydrolases degrade these lipids within lysosomes, where sequential removal of their structural components occurs. Deficiencies in these hydrolases result in the inability to degrade complex lipids and accumulate ceramides, causing damage to various tissues and organs, particularly the central nervous system, and leading to symptoms such as neurodegeneration, mental retardation, and psychomotor retardation. Sphingolipidoses are classified based on the accumulation of specific lipids. The various sphingolipidoses are caused by genetic defects in the lysosomal hydrolases or their activator proteins, leading to impaired degradation of sphingolipids. A diagnosis is made through clinical examination, measurement of lysosomal enzyme activities in blood cells or skin fibroblasts, and genetic investigations or biopsy of accessible tissues.
- In general, sphingolipidoses have an incidence of approximately 1 in 10,000 individuals.
Thelansis’s “Sphingolipidoses Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Sphingolipidoses treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).
KOLs insights of Sphingolipidoses across 8 MM market from the centre of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs.
Sphingolipidoses Market Forecast Patient Based Forecast Model (MS. Excel Based Automated Dashboard), which Data Inputs with sourcing, Market Event, and Product Event, Country specific Forecast Model, Market uptake and patient share uptake, Attribute Analysis, Analog Analysis, Disease burden, and pricing scenario, Summary, and Insights.
Thelansis Competitive Intelligence (CI) practice has been established based on a deep understanding of the pharma/biotech business environment to provide an optimized support system to all levels of the decision-making process. It enables business leaders in forward-thinking and proactive decision-making. Thelansis supports scientific and commercial teams in seamless CI support by creating an AI/ ML-based technology-driven platform that manages the data flow from primary and secondary sources.
Comments
Post a Comment